Neurocrine Biosciences (NBIX) Balance Sheet

Click line-items for a historical chart and %

Cash and cash equivalents	99.76M
Short-term investments, available for sale
Receivables under collaboration agreements
Other current assets	4.85M
Total current assets	357.89M
Property and equipment, net	6.18M
Long-term investments
Restricted cash	4.88M
Total assets	399.16M
Accounts payable	1.72M
Accrued liabilities	20.75M
Current portion of deferred revenues
Current portion of cease-use liability	265K
Current portion of deferred gain on sale of real estate	3.5M
Total current liabilities	26.67M
Deferred revenues	10.23M
Deferred gain on sale of real estate	8.26M
Deferred rent	1.59M
Cease-use liability	649K
Other liabilities	113K
Total liabilities	47.51M
Commitments and contingencies	0
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding	0
Common stock, $0.001 par value; 110,000,000 shares authorized; issued and outstanding shares were 55,236,896 as of June 30, 2011 and 54,882,129 as of December 31, 2010	87K
Additional paid-in capital
Accumulated other comprehensive loss	-187K
Accumulated deficit	-1.01B
Total stockholders' equity	351.65M
Total liabilities and stockholders' equity	399.16M

Entities mentioned with NBIX

View All Entities